<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347227</url>
  </required_header>
  <id_info>
    <org_study_id>20170</org_study_id>
    <nct_id>NCT03347227</nct_id>
  </id_info>
  <brief_title>Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation</brief_title>
  <acronym>COAST-AF RCT</acronym>
  <official_title>Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation (Coast-AF) Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, parallel group, two arm, single-blinded randomized clinical trial, assessing
      the efficacy of a patient-tailored catheter ablation (CA) strategy guided by atrial scar
      mapping in addition to pulmonary vein isolation (PVI) when compared to PVI alone in patients
      with persistent atrial fibrillation (AF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal CA strategy for persistent AF remains unknown. Current data highlight the need
      for a better understanding of the substrate and mechanisms of arrhythmia maintenance in this
      population. Atrial scar-based catheter ablation has recently emerged as a promising strategy
      for ablation of AF. However, the available data has limitations that preclude definitive
      conclusions regarding the utility of this strategy (no data from multicenter, randomized
      studies available). Further research is needed to assess the role of scar-based ablation for
      persistent AF.

      The Investigators hypothesize that catheter ablation of persistent AF (PeAF) tailored to
      abolish abnormal atrial substrate identified by intracardiac atrial scar mapping in addition
      to pulmonary vein isolation (PVI) will result in higher procedural success rates when
      compared to PVI alone.

      The study will recruit 502 patients with PeAF (251 per treatment arm) who are candidates for
      CA ablation of AF according to the treating physician (and in agreement with current practice
      guidelines). Subjects will be recruited over a 42 month period. The total duration of the
      study is 60 months.

      Prior to undergoing catheter ablation subjects will be seen by the investigator/ research
      assistant and the following data will be collected:

      i. Age and sex ii. Structural heart disease if present iii. CHADS2VASc score iv. DR-FLASH
      score v. NYHA class vi. Current medications vii. Duration of uninterrupted AF viii. Height
      and weight ix. Echocardiogram and other cardiac imaging results (within previous 12 months,
      including assessment of left ventricular ejection fraction, left atrial volume and valve
      function) x. ECG, Holter or loop monitor recording (within past 36 months) documenting AF.

      Subjects will be randomly assigned in a 1:1 ratio to undergo wide area circumferential
      ablation for pulmonary vein isolation (PVI- control arm) or wide area circumferential
      ablation PVI and scar ablation (experimental arm). Randomization will be stratified by centre
      and by sex. Subjects will be randomized prior to the procedure.

      Enrolled subjects will have a clinical follow-up visit at 3, 6, 12 and 18 months after the
      ablation procedure. A 14-day continuous ambulatory ECG monitor will be completed at each
      visit. The results of monitoring will be interpreted at a centralized core lab, and the
      results will be adjudicated by an arrhythmia specialist blinded to treatment group. A total
      of three questionnaires will be administered throughout the study, each at a specific time
      point. The Quality of Life (EQ-5D), CCS-Severity of AF scale, and Atrial Fibrillation Effect
      on Quality of life (AFEQT) will be completed at baseline, and at the 12-month and 18 month
      visit.

      Concomitant medical therapy will be selected according to the treating physician. All
      subjects will be maintained on systemic oral anticoagulation for at least 2 months following
      catheter ablation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, parallel arm randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of documented (&gt;30s) AF, atrial flutter or atrial tachycardia occuring from day 91 to 18 months post ablation</measure>
    <time_frame>day 91 post ablation to 18 months</time_frame>
    <description>Documented AF, Aflutter or AT by ECG, holter or external loop monitoring and has a duration of at least 30 seconds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AF burden</measure>
    <time_frame>At 12 months and 18 monts</time_frame>
    <description>Documented amount of AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for repeat ablation procedure for AF, AFl or AT</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Documented by ECG, holter or ECG loop recorder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for emergency room visits or hospitalization</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Hospital admission for &gt; 24 hours and emergency room admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any ECG documented AF with 90 days of ablation</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Symptomatic or asymptomatic AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first recurrence at 18 months according to sex and atrial scar extent</measure>
    <time_frame>18 months</time_frame>
    <description>Recurrence of AF, AFl or AT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite safety outcome</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Procedure related complications at any time (stroke, PV stenosis, pericarditis, cardiac perforation, major bleeding) and/or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ablation delivery time</measure>
    <time_frame>Day of ablation procedure</time_frame>
    <description>RF ablation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure duration</measure>
    <time_frame>Day of ablation procedure</time_frame>
    <description>Start of ablation to end of ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life analyses</measure>
    <time_frame>18 months</time_frame>
    <description>Using EQ-5D general quality of life score, and AF severity scale (symptoms and functionality)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">502</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pulmonary Vein Isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wide area circumferential catheter ablation for pulmonary vein isolation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Vein Isolation and scar ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wide area circumferential catheter ablation for pulmonary vein isolation and scar ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation</intervention_name>
    <description>Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation</description>
    <arm_group_label>Pulmonary Vein Isolation</arm_group_label>
    <arm_group_label>Pulmonary Vein Isolation and scar ablation</arm_group_label>
    <other_name>Atrial Fibrillation Ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥18 years ;

          2. Subjects with symptomatic persistent AF AND clinically indicated catheter ablation for
             AF

          3. At least one episode of AF that is sustained beyond 3 months in duration ; documented
             on 12-lead ECG, Holter monitor, loop monitor or trans-telephonic monitor (TTM) within
             36 months of enrollment in the study;

          4. Modified DR-FLASH score &gt;=4

        4. Subjects must be able to provide informed consent.

        Exclusion Criteria:

          1. History of previous catheter ablation for AF or left atrial flutter;

          2. History of previous surgical ablation for AF;

          3. Known intracardiac thrombus;

          4. Contraindication to systemic oral anticoagulation therapy;

          5. Reversible causes of AF;

          6. Hypertrophic cardiomyopathy;

          7. Severe valvular disease (mitral/aortic stenosis or regurgitation);

          8. Subjects that are pregnant or breastfeeding;

          9. Comorbid condition with life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Nery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo Nery, MD</last_name>
    <phone>613-696-7272</phone>
    <email>pnery@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen MacDonald</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>17077</phone_ext>
    <email>kmacdonald@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Veenhuyzen, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Veenhuyzen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Andrade, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jason Andrade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre, Nova Scotia Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Sapp, MD</last_name>
    </contact>
    <investigator>
      <last_name>John Sapp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Wong, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jorge Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allan Skanes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Allan Skanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atul Verma, MD</last_name>
    </contact>
    <investigator>
      <last_name>Atul Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Nery, MD</last_name>
      <phone>613-696-7272</phone>
      <email>pnery@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>David Birnie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Nery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Angaran, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paul Angaran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouge Valley Regional Heart Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Yung, MD</last_name>
    </contact>
    <investigator>
      <last_name>Derek Yung, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc Raymond, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Marc Raymond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacre-Coeur Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Sturmer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mario Sturmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidal Essebag, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jacqueline Joza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Macle, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Macle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Universitaire de Cardiologie et Pneumologie du Quebec (IUCPQ)</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Nault, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle Nault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de L'Estrie-CHUS-Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Dussault, MD</last_name>
    </contact>
    <investigator>
      <last_name>Charles Dussault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF ablation</keyword>
  <keyword>Pulmonary vein isolation</keyword>
  <keyword>Atrial scar ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

